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Background
Coronary angiography and the extent of coronary lumi-
nal stenosis has historically been the main factor used in
guiding decisions regarding revascularisation in patients
with stable coronary artery disease. More recently,
revascularisation based on invasive fractional flow
reserve (FFR) measurements has been shown to result
in a significant benefit for event free survival. Cardiac
magnetic resonance (CMR) perfusion imaging has been
shown to be superior to nuclear perfusion imaging and
has the potential to become the non-invasive test of
choice.
Methods
The MR-INFORM study is a prospective, multi-centre,
randomized controlled, non-inferiority, outcome trial. It
will compare the efficacy of the two investigative strate-
gies for the management of patients with suspected cor-
onary artery disease. Patients presenting with stable
angina are randomized into two groups: The FFR-
INFORMED and the MR-INFORMED group (Figure 1).
All patients undergo CMR perfusion scanning at 1.5T
(various vendors) at baseline. The patients in the MR-
INFORMED arm of the trial will have their subsequent
management based on the results of the CMR scan.
Those patients with significant ischaemia will have cor-
onary angiography and revascularisation guided by the
results of the MR scan i.e stenting in arteries that
demonstrate ischaemia . All patients with non-signifi-
cant ischaemia will have medical therapy optimized. The
baseline scan in the FFR-INFORMED arm will remain
blinded and the patient will go on to have coronary
angiography with FFR measurement in those arteries
with a stenosis of 40 - 99%. The revascularisation deci-
sion in this group will be based on an FFR<0.8 below
which a stenosis is physiologically significant. All
patients will have a cardiovascular risk assessment at
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Figure 1 Study Flow diagram outlining the study design. *CXA =
Coronary Angiography.
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therapy is optimized.
The principal hypothesis is that selecting patients with
stable angina for revascularisation and optimal medical
therapy (OMT) or OMT alone based on CMR myocar-
dial perfusion is non-inferior to selecting patients based
on routine coronary angiography and fractional flow
reserve (FFR) in terms of subsequent major adverse car-
diac events.
The primary end-point will be the composite of major
adverse cardiac events at one year, defined as death, myo-
cardial infarction and repeat revascularisation (table 1).
Results
In recruitment phase.
Conclusions
T h eM R - I N F O R Mt r i a lw i l lc o m p a r et h er o l eo fM R
perfusion with routine coronary angiography and frac-
tional flow measurements for guiding the management
of patients with stable angina and an intermediate to
high likelihood of coronary artery disease. Noninferiority
of MR perfusion imaging to the current invasive refer-
ence standard (FFR) would establish MR perfusion ima-
ging as an attractive non-invasive alternative to current
diagnostic pathways. The results will help to inform
national and international guidelines on the investiga-
tion and management of coronary artery disease, and
ultimately lead to improved patient care.
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Table 1 Detailed definition of end-points
End Point Definition
Death All cause mortality
Myocardial
Infarction
Spontaneous Elevation of CK or Troponin above baseline with symptoms of ischaemia, ECG changes or imaging evidence of
loss of myocardium
Myocardial
Infarction
Peri-
procedural
CKMB >3X ULN- upper limit of normal (post PCI 12-24hrs) CKMB>5X ULN (post CABG 24-72 hours) plus new Q
waves or LBBB, new native vessel or graft occlusion, imaging evidence of loss of viable myocardium
Repeat
revascularisation
Repeat PCI or CABG of the target lesion performed for restenosis or other complication of the target lesion (from
5mm proximal to 5mm distal to the stent)
Hussain et al. Journal of Cardiovascular Magnetic Resonance 2012, 14(Suppl 1):O19
http://www.jcmr-online.com/content/14/S1/O19
Page 2 of 2